Drugs / ISA101
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02128126 | Sep 2013 → Aug 2018 | cervical cancer | ISA Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02426892 | Dec 2015 → Nov 2021 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISA 101 | “OBJECTIVE: To determine whether the efficacy of nivolumab, an anti-PD-1 immune checkpoint antibody, is amplified through treatment with ISA 101, a synthetic long-peptide HPV-16...” PMID 30267032 ↗ Jan 20192“The combination of ISA101, a human papilloma virus (HPV) 16 peptide vaccine, and nivolumab showed a promising response rate of 33% in patients with incurable HPV-16+ cancer.” PMID 35193933 ↗ Feb 2022 |
| Modality | Vaccine | “ISA101/ISA101b is a novel therapeutic synthetic long peptide (SLP) vaccine targeting HPV16” NCT02128126 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT02426892 ↗ |